Britain counters EU vaccine ban with 60m doses of new home made covid vaccine, Novavax
London, March 30, 2021 (AltAfrica)-Britain is to produce about 60 million doses of a new COVID vaccine Novavax in the next two months, Prime Minister Boris Johnson has announced. The announcement of a new vaccine solely produced in Britain appears
Boris Johnson revealed that the new Novavax vaccine which has yet to be approved – will undergo its “fill and finish” stage at a GlaxoSmithKline (GSK) facility.
Already, part of the vaccine is already being produced in the North East, of the country at a Fujifilm site in Billingham, Stockton-on-Tees, as it awaits approval from the Medicines and Healthcare products Regulatory Agency (MHRA).
The GSK facility – which will undertake the final step of the new Novavax vaccine manufacture from as early as May
#News for #investors and #media: We’ve reached an agreement in principle w/ @Novavax + the UK VTF to support manufacturing of up to 60 m doses of Novavax’ #COVID19 vaccine candidate for use in the UK. https://t.co/2vJ3z0P1eY pic.twitter.com/pjgoBWqSPH— GSK (@GSK) March 29, 2021
Speaking at a Downing Street news conference on Monday, Mr Johnson said: “I’ve already told you that Novavax – a potentially significant new weapon in our armoury against COVID – is going to be made at Fujifilm in the North East.
“And I can today announce that the vaccine taskforce has reached an agreement with GlaxoSmithKline to finish and bottle this precious fluid also in the North East.
“Giving us between 50 and 60 million doses of UK-made vaccine, subject to the right approvals from the MHRA.”
The prime minister did not specifically mention the GSK facility being used for the Novavax jab was its Barnard Castle site.
But Roger Connor, president of GSK vaccines, said in a statement: “GSK is delighted to support Novavax and the UK vaccines taskforce with this manufacturing arrangement for the UK and our Barnard Castle facility is now undertaking the rapid preparation work required to manufacture up to 60 million doses of this vaccine.
“We have ensured that we can deliver these volumes without impacting supply of our other vital medicines and vaccines, and without disruption to the other COVID-19 collaborations GSK is engaged in globally.”
The protein antigen component of the Novavax jab is being produced at the Fujifilm site, while GSK will prepare vials of the final vaccine at Barnard Castle and package them for distribution and use.
GSK said the Novavax vaccine has shown “strong potential efficacy” against coronavirus in phase three clinical trials, including against the COVID variant that was first discovered in Kent.
Health Secretary Matt Hancock said: “We’ve all seen just how important onshore vaccine manufacturing capabilities are, and this fantastic deal will ensure more of these vital products can be produced here in the UK.”
The NHS recently warned of a month-long “significant reduction” in vaccine supplies, with vaccination efforts in April to now concentrate on delivering people’s second doses.
However, ministers have said they remain on course to meet their target of offering a first dose of a COVID jab to the top nine priority groups by 15 April, as well as all UK adults by the end of July.
The supply problems follow delays to shipments from India, while they also come amid a vaccine row with the EU.